Reduction in size of renal angiomyolipoma after treatment with everolimus in lung transplantation due to lymphangioleiomyomatosis.

Abstract

Lymphangioleiomyomatosis (LAM) is a rare disease characterized by abnormal proliferation of immature smooth muscle cells and cystic lung destruction, which determines the prognosis of the disease. The kidney angiomyolipomas are usually very common in this disease and are usually asymptomatic unless complications arise. In the absence of a curative treatment, recent publications show promising results in molecular therapy to prevent functional decline and to control the size of the angiomyolipomas. These therapies include mTOR complex inhibitors, especially sirolimus. We report a case of a patient diagnosed with LAM who underwent lung transplantation with reduction of renal angiomyolipoma size after treatment with the mTOR inhibitor everolimus.

• Authors: Carlos Bujalance-Cabrera, José Manuel Vaquero-Barrios, Javier Redel-Montero, Laura Caballero-Ballesteros, Antonio Requejo-Jiménez, Francisco Santos-Luna
• Journal: Archivos de bronconeumologia (Arch Bronconeumol) Vol. 48 Issue 12 Pg. 479-81 (Dec 2012) ISSN: 1579-2129 [Electronic] Spain
• PMID: 22444789 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2012 SEPAR. Published by Elsevier Espana. All rights reserved.

Chemical References

• Antineoplastic Agents
• Everolimus
• Sirolimus

Topics

• Adult
• Angiomyolipoma (complications, drug therapy, pathology)
• Antineoplastic Agents (therapeutic use)
• Everolimus
• Female
• Humans
• Kidney Neoplasms (complications, drug therapy, pathology)
• Lung Transplantation
• Lymphangioleiomyomatosis (complications, surgery)
• Sirolimus (analogs & derivatives, therapeutic use)
• Tumor Burden